Module 6: Thresholds and Their Definition

Recorded On: 01/20/2020

image
image


Characterizing and interpreting the dose-response relationship is perhaps the most challenging task in health risk assessment. Toxicologists understand that “the dose makes the poison”, but the types of effects under consideration and the magnitude of their deviation from the “normal” range pose separate and appreciable challenges. In the context of EPA’s Reference Dose paradigm, some effects may not represent adverse changes; for other effects, some deviations, even if statistically significant, have been interpreted to not represent biologically meaningful changes. Application of benchmark dose modeling allows risk assessors to estimate doses associated with predetermined levels of response, often 10% for non-cancer effects, 5% for developmentally toxic effects, and 1% for cancer. These values and traditional NOAEL or LOAEL values may be used as point of departure (POD) values for determining risk. Whether defined in animals or humans in vivo, the POD is the “jumping off point” from which we depart from the realm of empirical dose-response data and begin to extrapolate the identified “point” to human exposure conditions that may differ relative to species, human population subgroup, exposure duration, and/or magnitude of effect. While the POD identified in vivo may (might, can) represent a threshold, the further that POD is extrapolated from the conditions under which it is identified, the less certain it becomes as a threshold (in fact, its name changes and its definition often acknowledges a potential range of uncertainty). The decisions surrounding what effect is selected as the critical effect, the acceptability of the study design employed to develop dose-response data, the selection of the point of departure, and the methods used to extrapolate the POD to the risk value each embody multiple considerations and decisions, carrying with them different levels of bias toward health conservatism – a condition which may not be fully acknowledged or appreciated. This presentation will explore aspects of risk value development focused on identifying and extrapolating the biological threshold for adversity.

John Lipscomb, PhD, DABT, ATS

John Lipscomb, PhD, DABT, ATS

Adjunct Professor

University of Louisville

Dr. Lipscomb began his career as a biologist at the National Center for Toxicological Research in Jefferson, Arkansas. He later served as a Captain (research toxicologist) in the US Air Force, where he earned the Air Force Achievement Medal for his pioneering work on the military’s first large-scale investigation of human metabolic variability. He completed his federal career as a toxicologist and risk assessor in EPA’s National Center for Environmental Assessment and National Homeland Security Research Center in Ohio, where he was a chemical manager for three different risk assessment programs and led the development of EPA guidance for quantitative risk assessment and emergency exposure guidance values. Dr. Lipscomb has over 100 peer-reviewed publications, book chapters, and government technical reports. His interests include quantitative risk assessments of single chemicals and chemical mixtures, in vitro to in vivo extrapolation, toxicokinetics, and non-default extrapolations of dosimetry among and between species. Dr. Lipscomb is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences. He serves on the Health Advisory Board for NSF International and the American Industrial Hygiene Association’s Emergency Response Planning Committee. He is a past president of the Society for Risk Analysis’s Ohio chapter, the Society of Toxicology’s Risk Assessment Specialty Section and Ohio Valley regional chapter, as well as the American Board of Toxicology. He serves on the Editorial Board for Toxicological Sciences and is an Associate Editor for Toxicology Mechanisms and Methods, and Toxicology Reports. Dr. Lipscomb holds bachelor’s and master’s degrees in biology from the University of Central Arkansas and a PhD in interdisciplinary toxicology from the University of Arkansas for Medical Sciences, and is an adjunct professor of Toxicology and course director for Human Health Risk Assessment in the Department of Pharmacology and Toxicology at the University of Louisville.

Key:

Complete
Failed
Available
Locked
Module 6: Thresholds and Their Definition
Module 6: Thresholds and Their Definition, John Lipscomb, PhD, DABT, ATS
Recorded 01/20/2020  |  90 minutes
Recorded 01/20/2020  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.